Mammalian target of rapamycin (mTOR) inhibitors could be associated with acute nephrotoxicity, according to French researchers. The team describes 4 cancer patients who developed severe acute kidney ...
A protein once thought to simply help cancer cells avoid death turns out to do much more. MCL1 actively drives cancer ...
Washington, DC-Rapamycin, aka sirolimus, a drug already used as an immunosuppressant agent in kidney transplantation, may prove to be an effective treatment for autosomal dominant polycystic kidney ...
Researchers at Zhejiang University and Zhongshan Institute for Drug Discovery have discovered phosphatidylinositol 3-kinase δ (PI3Kδ) and mammalian target of rapamycin (mTOR; FRAP1) dual inhibitors ...
Rapamycin has been trending on social media, where biohackers such as Dr. Peter Attia and Bryan Johnson tout it as the “gold standard” for people seeking to live a longer, healthier life. Rapamycin is ...
Groundbreaking studies in mice have sparked a frenzy among longevity enthusiasts—but human trials are still in their infancy. Rapamycin (red) inhibits a protein complex called mTORC1 (mammalian target ...
A new study reveals how a single cancer protein may simultaneously drive tumor survival and metabolic control, uncovering a ...
Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with ...
Clears the way to finalize Phase 3 protocol and recruit sites for U.S. Phase 3 substantially funded by $17.0 million CPRIT grant and $8.5 million Company match Biodexa Pharmaceuticals PLC (“Biodexa” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback